By Kwanwoo Jun

 

South Korea's LG Chem Ltd. has decided to acquire U.S. biotech company AVEO Pharmaceuticals Inc. for $566 million to enter the U.S. cancer treatment market.

The acquisition deal will be completed by the first quarter of 2023, LG Chem said in a regulatory filing late Tuesday after its board approved it.

The deal still needs approval from AVEO shareholders and U.S. regulators for its completion, LG Chem said.

The planned acquisition is the latest in LG Chem's push to diversify its previously petrochemicals-focused business into biotech and other industries.

AVEO Pharmaceuticals said it was marketing Fotivda, a prescription medicine used to treat adults with advanced kidney cancer, in the U.S.

 

Write to Kwanwoo Jun at kwanwoo.jun@wsj.com

 

(END) Dow Jones Newswires

October 18, 2022 05:50 ET (09:50 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni AVEO Pharmaceuticals (NASDAQ:AVEO)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di AVEO Pharmaceuticals
Grafico Azioni AVEO Pharmaceuticals (NASDAQ:AVEO)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di AVEO Pharmaceuticals